神経変性疾患研究セクター

セクター概要

神経変性疾患の神経症状と脳画像をつなぎ、生体脳内で起こっていることを見える化します。画像情報と関連する大切な臨床情報を見つけ出し、より早期かつ正確な診断法の確立を目指します。

セクター長

免許・資格

• 2008年- 医師免許取得
• 2011年- 日本内科学会　認定内科医
• 2014年- 日本神経学会　神経内科専門医
• 2017年- 日本認知症学会　認知症専門医
• 2017年- 日本内科学会　総合内科専門医

≪受賞歴≫

• 第62回　日本神経学会学術大会　最優秀口演賞 (臨床部門) (2021年)
  「Establishment of diagnostic system for progressive supranuclear palsy using in vivo tau imaging」
• 第40回　日本認知症学会学術集会　学会奨励賞 (臨床部門) (2021年)
  「タウPETを用いた機械学習に基づく非アルツハイマー型認知症の自動診断法開発」

原著論文

1. 1. Kubota M, Endo H, Takahata K, Tagai K, Suzuki H, Onaya M, Sano Y, Yamamoto Y, Kurose S, Matsuoka K, Seki C, Shinotoh H, Kawamura K, Zhang MR, Takado Y, Shimada H, Higuchi M. In vivo PET classification of tau pathologies in patients with frontotemporal dementia. Brain Commun, 2024, DOI: 10.1093/braincomms/fcae075.
2. 2. Matsuoka K, Hirata K, Kokubo N, Maeda T, Tagai K, Endo H, Takahata K, Shinotoh H, Ono M, Seki C, Tatebe H, Kawamura K, Zhang MR, Shimada H, Tokuda T, Higuchi M, Takado Y. Investigating neural dysfunction with abnormal protein deposition in Alzheimer's disease through magnetic resonance spectroscopic imaging, plasma biomarkers, and positron emission tomography. NeuroImage Clin, 2023, 41, 103560-103560.
3. 3. Hirata K, Matsuoka K, Tagai K, Endo H, Tatebe H, Ono M, Kokubo N, Oyama A, Shinotoh H, Takahata K, Obata T, Dehghani M, Near J, Kawamura K, Zhang MR, Shimada H, Yokota T, Tokuda T, Higuchi M, Takado Y. Altered Brain Energy Metabolism Related to Astrocytes in Alzheimer's Disease. Ann Neurol, 2023, DOI: 10.1002/ana.26797.
4. 4. Kitamura S, Kimura Y, Takahata K, Moriguchi S, Kubota M, Shimada H, Endo H, Takado Y, Kawamura K, Zhang MR, Suhara T, Higuchi M. Serotonergic neurotransmission in limbic regions may reflect therapeutic response of depressive patients: A PET study with 11C-WAY-100635 and 18F-MPPF. Int J Neuropsychopharmacol. 2023; 26(7): 474-482.
5. 5. Nunomura H, Kasahara T, Hatano T, Shimada H, Takado Y, Endo H, Inoshita A, Inomata A, Murofushi T, Misawa S, Machida Y, Imai H. Front Neurol. 2023; 14: 1100931.
6. 6. Matsuoka K, Takado Y, Tagai K, Kubota M, Sano Y, Takahata K, Ono M, Seki C, Matsumoto H, Endo H, Shinotoh H, Sahara Y, Obata T, Jamie N, Kawamura K, Zhang MR, Suhara T, Shimada H, Higuchi M. Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy. J Neurol Sci. 2022; 444: 120514.
7. 7. Tagai K, Ikoma Y, Endo H, Debnath OB, Seki C, Matsuoka K, Matsumoto H, Oya M, Hirata K, Shinotoh H, Takahata K, Kurose S, Sano Y, Ono M, Shimada H, Kawamura K, Zhang MR, Takado Y, Higuchi M. An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with 18F-PM-PBB3 (18F-APN-1607). Neuroimage. 2022; 264: 119763.
8. 8. Endo H, Tagai K, Ono M, Ikoma Y, Oyama A, Matsuoka K, Kokubo N, Hirata K, Sano Y, Oya M, Matsumoto H, Kurose S, Seki C, Shimizu H, Kakita A, Takahata K, Shinoto H, Shimada H, Tokuda T, Kawamura K, Zhang MR, Oishi K, Mori S, Takado Y, Higuchi M. A Machine Learning–Based Approach to Discrimination of Tauopathies Using [18F]PM-PBB3 PET Images. Mov Disord. 2022; 37(11): 2236-2246.
9. 9. Matsuoka K, Ono M, Takado Y, Hirata K, Endo H, Ohfusa T, Kojima T, Yamamoto T, Onishi T, Orihara A, Tagai K, Takahata K, Seki C, Shinotoh H, Kawamura K, Shimizu H, Shimada H, Kakita A, Zhang MR, Suhara T, Higuchi M. High-Contrast Imaging of α-Synuclein Pathologies in Living Patients with Multiple System Atrophy. Mov Disord. 2022; 37(10): 2159-2161.
10. 10. Nakano Y, Shimada H, Shinotoh H, Hirano S, Tagai K, Sano Y, Yamamoto Y, Endo H, Matsuoka K, Takahata K, Kubota M, Takado Y, Kimura Y, Ichise M, Ono M, Sahara N, Kawamura K, Zhang MR, Kuwabara S, Suhara T, Higuchi M．PET-based classification of corticobasal syndrome．Parkinsonism Relat Disord. 2022; 98(1): 92-98.
11. 11. Takahata K, Seki C, Kimura Y, Kubota M, Ichise M, Sano Y, Yamamoto Y, Tagai K, Shimada H, Kitamura S, Matsuoka K, Endo H, Shinotoh H, Kawamura K, Zhang MR, Takado Y, Higuchi M. First-in-human in vivo undefined imaging and quantification of monoacylglycerol lipase in the brain: a PET study with 18 F-T-401. Eur J Nucl Med Mol Imaging. 2022; Online ahead of print.
12. 12. Mano T, Nakayama T, Endo H, Bono K, Imafuku I. Non-invasive visualization of arterial stagnation in a dissected internal carotid artery. J Neurol Sci. 2020; 412: 116760.
13. 13. Endo H, Shimada H, Sahara N, Ono M, Koga S, Kitamura S, Niwa F, Hirano S, Kimura Y, Ichise M, Shinotoh H, Zhang MR, Kuwabara S, Dickson DW, Toda T, Suhara T, Higuchi M. In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy. Mov Disord. 2019; 34(5): 744-754.
14. 14. Shinotoh H, Shimada H, Kokubo Y, Tagai K, Niwa F, Kitamura S, Endo H, Ono M, Kimura Y, Hirano S, Mimuro M, Ichise M, Sahara N, Zhang MR, Suhara T, Higuchi M. Tau imaging detects distinctive distribution of tau pathology in ALS/PDC on the Kii Peninsula. Neurology. 2019; 92(2): e136-e147.
15. 15. Endo H, Sekiguchi K, Shimada H, Ueda T, Kowa H, Kanda F, Toda T. Low signal intensity in motor cortex on susceptibility-weighted MR imaging is correlated with clinical signs of amyotrophic lateral sclerosis: a pilot study. J Neurol. 2018; 265: 552-561.
16. 16. Kitamura S, Shimada H, Niwa F, Endo H, Shinotoh H, Takahata K, Kubota M, Takado Y,Hirano S, Kimura Y, Zhang MR, Kuwabara S, Suhara T, Higuchi M. Tau-induced focal neurotoxicity and network disruption related to apathy in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2018; 89: 1208-1214.
17. 17. Endo H, Sekiguchi K, Ueda T, Kowa H, Kanda F, Toda T. Regional glucose hypometabolic spread within the primary motor cortex is associated with amyotrophic lateral sclerosis disease progression: A fluoro-deoxyglucose positron emission tomography study. eNeurologicalSci. 2017; 6: 74-79.
18. 18. Endo H, Uenaka T, Satake W, Suzuki Y, Tachibana H, Chihara N, Ueda T, Sekiguchi K, Taniguchi-Ikeda M, Kowa H, Kanda F, Toda T. Japanese WDR45 de novo mutation diagnosed by exome analysis: A case report. Neurology and Clinical Neuroscience. 2017; 5: 131-133.
19. 19. Shimada H, Kitamura S, Shinotoh H, Endo H, Niwa F, Hirano S, Kimura Y, Zhang MR, Kuwabara S, Suhara T, Higuchi M. Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study. Alzheimers Dement (Amst). 2017; 6: 11-20.
20. 20. Takahata K, Kimura Y, Seki C, Tokunaga M, Ichise M, Kawamura K, Ono M, Kitamura S, Kubota M, Moriguchi S, Ishii T, Takado Y, Niwa F, Endo H, Nagashima T, Ikoma Y, Zhang MR, Suhara T, Higuchi M. A human PET study of [11C]HMS011, a potential radioligand for AMPA receptors. EJNMMI Res. 2017; 7: 1-10.
21. 21. Kimura Y, Endo H, Ichise M, Shimada H, Seki C, Ikoma Y, Shinotoh H, Yamada M, Higuchi M, Zhang MR, Suhara T. A new method to quantify tau pathologies with (11)C-PBB3 PET using reference tissue voxels extracted from brain cortical gray matter. EJNMMI Res. 2016; 6: 1-6.
22. 22. Kimura Y, Seki C, Ikoma Y, Ichise M, Kawamura K, Takahata K, Moriguchi S, Nagashima T, Ishii T, Kitamura S, Niwa F, Endo H, Yamada M, Higuchi M, Zhang MR, Suhara T. [(11)C]TASP457, a novel PET ligand for histamine H3 receptors in human brain. Eur J Nucl Med Mol Imaging. 2016; 43: 1653-1663.
23. 23. Endo H, Chihara N, Sekiguchi K, Kowa H, Kanda F, Toda T. A case of multiple sclerosis who relapsed early after fingolimod therapy introduced. Clin Neurol. 2015; 55: 417-420.

総説

1. 片岡優子，遠藤浩信，樋口真人．PETを用いた神経変性疾患の早期診断．実験医学増刊．2023; 41: 214-220.
2. 高堂裕平，互健二，小野麻衣子，遠藤浩信，樋口真人．Tauイメージング：疾患修飾療法開発に直結する次世代型PET研究．脳神経内科．2022; 96: 474-480.
3. 小野麻衣子，遠藤浩信，高堂裕平，張明栄，樋口真人．αシヌクレイン・イメージング．脳神経内科．2022; 86: 481-486.
4. 遠藤浩信，島田斉．ADの早期診断におけるバイオマーカーの役割はどのようなことか．Geriatric Medicine. 2021; 59: 191-194．
5. 島田斉，遠藤浩信，須原哲也．タウイメージングによる認知症の診断．臨床精神医学．2016; 45: 441-445.
6. 遠藤浩信，島田斉．進行性核上性麻痺と大脳皮質基底核症候群のtau PET. 神経内科．2015; 82: 153-159.
7. 遠藤浩信，佐原成彦，島田斉．Tau PET. Clinical Neuroscience. 2015; 33: 1156-1158.
8. 遠藤浩信, 島田斉，樋口真人，篠遠仁，須原哲也．精神・神経疾患における分子イメージングの現状と展望．インナービジョン．2014; 29: 58-62.